Pharmaust Ltd
ASX:PAA
Pharmaust Ltd
Research & Development
Pharmaust Ltd
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Pharmaust Ltd
ASX:PAA
|
Research & Development
-AU$3.8m
|
CAGR 3-Years
-91%
|
CAGR 5-Years
-30%
|
CAGR 10-Years
-34%
|
|
|
Recce Pharmaceuticals Ltd
ASX:RCE
|
Research & Development
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Mayne Pharma Group Ltd
ASX:MYX
|
Research & Development
-AU$17.9m
|
CAGR 3-Years
-14%
|
CAGR 5-Years
4%
|
CAGR 10-Years
N/A
|
|
|
Neuren Pharmaceuticals Ltd
ASX:NEU
|
Research & Development
-AU$30m
|
CAGR 3-Years
-58%
|
CAGR 5-Years
-33%
|
CAGR 10-Years
-9%
|
|
|
C
|
Clarity Pharmaceuticals Ltd
ASX:CU6
|
Research & Development
-AU$66.9m
|
CAGR 3-Years
-52%
|
CAGR 5-Years
-57%
|
CAGR 10-Years
N/A
|
|
|
Nyrada Inc
ASX:NYR
|
Research & Development
-AU$4.4m
|
CAGR 3-Years
-34%
|
CAGR 5-Years
-26%
|
CAGR 10-Years
N/A
|
|
Pharmaust Ltd
Glance View
PharmAust Ltd. is a pharmaceutical company, which provides products and services in synthetic and medicinal chemistry to the drug discovery and pharmaceutical industries. The company is headquartered in Nedlands, Western Australia. The company went IPO on 2001-10-05. The firm is focused on developing therapeutics for cancer, neurodegenerative diseases and viral infections in humans and cancer for pet dogs. The firm's lead candidate, monepantel (MPL), is a small molecule drug primarily being developed as a safe and potent treatment for cancer. The MPL can also be used for neurodegenerative diseases such as Motor Neuron Disease, Parkinson's Disease, and Alzheimer's Disease. The company has completed Phase I clinical trials with MPL in humans and dogs diagnosed with solid tumors. The firm has also initiated a preclinical program to screen its portfolio of aminoacetonitrile (AAD) compounds for anticancer activity.
See Also
What is Pharmaust Ltd's Research & Development?
Research & Development
-3.8m
AUD
Based on the financial report for Jun 30, 2024, Pharmaust Ltd's Research & Development amounts to -3.8m AUD.
What is Pharmaust Ltd's Research & Development growth rate?
Research & Development CAGR 10Y
-34%
Over the last year, the Research & Development growth was -273%. The average annual Research & Development growth rates for Pharmaust Ltd have been -91% over the past three years , -30% over the past five years , and -34% over the past ten years .
